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A B S T R A C T
Background
People with cystic fibrosis and pancreatic insufficiency are at risk of fat soluble vitamin deficiency as these vitamins (A, D, E and K)
are co-absorbed with fat. Thus, some cystic fibrosis centres routinely administer these vitamins as supplements but the centres vary in
their approach of addressing the possible development of deficiencies in these vitamins. Vitamin A deficiency causes predominantly
eye and skin problems while supplementation of vitamin A to excessive levels may cause harm to the respiratory and skeletal systems
in children. Thus a systematic review on vitamin A supplementation in people with cystic fibrosis would help guide clinical practice.
Objectives
To determine if vitamin A supplementation in children and adults with CF:
1. reduces the frequency of vitamin A deficiency disorders;
2. improves general and respiratory health;
3. increases the frequency of vitamin A toxicity.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from
comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Date of the most recent search of the Group’s Cystic Fibrosis Trials Register: 23 May 2012.
Selection criteria
All randomised or quasi-randomised controlled trials comparing all preparations of oral vitamin A used as a supplement compared to
either no supplementation (or placebo) at any dose and for any duration, in children or adults with cystic fibrosis (defined by sweat
tests or genetic testing) with and without pancreatic insufficiency.
Data collection and analysis
No relevant studies for inclusion were identified in the search.
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Main results
No studies were included in this review.
Authors’ conclusions
As there were no randomised or quasi-randomised controlled trials identified, we cannot draw any conclusions on the benefits (or
otherwise) of regular administration of vitamin A in people with cystic fibrosis. Until further data are available, country or region
specific guidelines on the use of vitamin A in people with cystic fibrosis should be followed.
P L A I N L A N G U A G E S U M M A R Y
The use of regular vitamin A preparations for children and adults with cystic fibrosis
Cystic fibrosis can cause certain vitamins, such as vitamin A, to be inadequately absorbed leading to problems caused by vitamin
deficiency. Lack of vitamin A (vitamin A deficiency) can cause specific problems such as eye and skin problems. It can also be associated
with poorer general and respiratory health. Thus people with cystic fibrosis are usually given regular vitamin A preparations from
a very young age. However, excess vitamin A can also cause respiratory and bone problems. The review found no studies to show
whether giving vitamin A regularly for people with cystic fibrosis is beneficial or not. The authors are unable to draw any conclusions
regarding the routine administration of vitamin A supplements and recommend that until further evidence is available, local guidelines
are followed regarding this practice.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a genetic disorder that affects multiple or-
gans. Pancreatic insufficiency affects up to 90% of people with CF,
whereby fat malabsorption occurs and pancreatic enzyme replace-
ment is required to prevent steatorrhoea and malnutrition (Dodge
2006). Fat soluble vitamins (A, D, E and K) are co-absorbed with
fat and thus deficiency of these vitamins may occur (Dodge 2006).
Some CF centres routinely administer these vitamins as supple-
ments from the neonatal period, whilst others administer them
only later in life or when deficiencies are detected clinically or on
routine monitoring. While deficiencies may occur from the dis-
ease process of CF and insufficient supplementation, vitamin tox-
icity may also occur from excess supplementation. Both deficiency
and excess of these vitamins may lead to specific medical problems
(Dodge 2006; Sethuraman 2006).
Vitamin A is an essential nutrient for epithelial cell maintenance
and repair in the respiratory, urinary and intestinal tract, im-
mune response, and bone growth (DAA 2006). Dietary vitamin A
(retinol or retinol esters) is found in liver, beef, eggs, fish, the fat of
dairy products and vitamin A fortifiedmargarine. Beta- and alpha-
carotene can act as precursors for the synthesis of vitamin A. The
dietary carotenoid (beta-carotene) is found in red, orange, yellow
and leafy green vegetables (e.g. carrots, sweet potato, silverbeet)
and red and orange fruit (e.g. mangos, oranges).
Vitamin A deficiency can be defined as serum retinol (SROL)
concentration less than 0.70 µmol/L (less than 20 µg/dl) (West
2003). However, SROL levels may be influenced by albumin and
retinol binding protein (RBP) as well as acute illnesses with infec-
tion and inflammation (Napoli 1996; Stephensen 1994). SROL
levels should be measured during clinical stability (DAA 2006).
The major consequence of vitamin A deficiency is ocular (eye)
with abnormal dark adaptation (night blindness), conjunctival and
corneal xerosis (thickening) which can lead to blindness (DAA
2006; West 2003). Another consequence of vitamin A deficiency
is the skin condition phrynoderma (a form of follicular hyperker-
atosis associated with some micronutrient deficiencies). Vitamin
A deficiency has also been linked to impaired mechanisms of host
resistance to infection, poor growth and increased mortality in a
study of mothers and children (West 2003).
Description of the intervention
Vitamin A is available as a sole supplement as well as in com-
bination form with other vitamins as multi-vitamins (either as a
liquid or a tablet). The availability of different formulations differ
in different health services (Graham-Maar 2006). Vitamin A is
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usually administered as a daily dose, but the recommended doses
vary in different guidelines. For example, the Royal Brompton
Hospital guidelines recommend 4000 IU for children aged under
one year, then 4000 to 10,000 IU for all other age groups (Royal
Brompton Hospital 2011); and the USA guidelines recommend
3000 µg retinol activity equivalents (approximately 10,000 IU)
(Graham-Maar 2006).
How the intervention might work
Normalisation of vitamin A levels may avoid the afore-mentioned
problems.However supplementation of these vitamins to excessive
levels may cause harm to the respiratory system, the skeletal sys-
tem (osteoporosis and fractures) and liver abnormality (Penniston
2006) in children with and without CF (Graham-Maar 2006;
Sethuraman 2006).
Why it is important to do this review
The approach of addressing the possibility of the development de-
ficiency of these fat soluble vitamins is variable among CF centres.
Thus a systematic review on the efficacy of vitamins A, D, E and
K supplementation in children and adults with CF in prevent-
ing effects of the deficiency of these vitamins would help guide
clinical practice. Supplementation of vitamins D, E and K will be
addressed in other Cochrane Systematic Reviews (Ferguson 2012;
Jagannath 2011; Okebukola 2011; Shamseer 2010). This review
will evaluate vitamin A supplementation in children and adults
with CF.
O B J E C T I V E S
To determine if vitamin A supplementation in children and adults
with CF:
1. reduces the frequency of vitamin A deficiency disorders;
2. improves general and respiratory health;
3. increases the frequency of vitamin A toxicity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised (RCTs) and quasi-randomised trials (controlled clin-
ical trials).
Types of participants
Children or adults with CF (defined by sweat tests or genetic
testing) with and without pancreatic insufficiency.
Types of interventions
All preparations of oral vitamin A used as a supplement compared
to either no supplementation or placebo at any dose for at least
three months.
Types of outcome measures
Weplanned to obtain data on at least one of the following outcome
measures:
Primary outcomes
1. Vitamin A deficiency disorders
i) visual impairment
ii) any other ocular dysfunction
iii) skin manifestations (e.g. phrynoderma)
2. Growth and nutritional status (e.g. weight, height, body
mass index, z score for weight, etc.)
3. Mortality
Secondary outcomes
1. Respiratory outcomes
i) bronchiectasis severity control (e.g. Likert scale, visual
analogue scale or radiological score (Marchant 2001))
ii) lung function indices (spirometry e.g. FEV1 and FVC)
iii) proportions of participants who had respiratory
exacerbations or hospitalisations or both
iv) total number of hospitalised days or days off work or
school
2. Quality of life
3. Adverse events (e.g. vomiting, loss of appetite, osteoporosis,
fractures or any other adverse event noted)
4. Possible toxicity events (e.g. liver dysfunction)
5. Measured levels of vitamin A
We planned to evaluate outcomes based on
1. short term (12 months or less), and
2. medium to long term (longer than one year)
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Search methods for identification of studies
Electronic searches
We attempted to identify relevant studies from the Group’s Cystic
Fibrosis Trials Register using the term ’vitamin A’.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of EMBASE to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching through the abstract books of three major
cystic fibrosis conferences: the International Cystic Fibrosis Con-
ference; the European Cystic Fibrosis Conference and the North
American Cystic Fibrosis Conference. For full details of all search-
ing activities for the register, please see the relevant sections of the
Cystic Fibrosis and Genetic Disorders Group Module.
Date of the most recent search of the Group’s Cystic Fibrosis Trials
Register: 23 May 2012.
Searching other resources
Searches of bibliographies and texts of selected studies were also
conducted to identify additional studies.
Data collection and analysis
The authors did not apply the process described below since no
studies were identified. In future updates of this review, the authors
will apply the following methods if studies are identified:
Selection of studies
From the title, abstract, or descriptors, two authors will indepen-
dently review results of the literature searches to identify studies
potentially relevant to the review according to our inclusion cri-
teria for further assessment. From these studies, the same two au-
thors will independently examine the papers in further detail in
order to select studies for inclusion using the criteria stated before.
The authors will resolve disagreement by consensus.
Data extraction and management
The authors will review studies that satisfy the inclusion criteria
for the review and independently extract data on the outcomes
described as follows: study setting; year of study; source of fund-
ing; participant recruitment details (including number of eligi-
ble participants); inclusion and exclusion criteria; randomisation
and allocation concealment method; numbers of participants ran-
domised; blinding (masking) of participants, care providers and
outcome assessors; dose and type of intervention; duration of ther-
apy; co-interventions; numbers of participants not followed up;
reasons for withdrawals from study protocol (clinical, side effects,
refusal and other); side effects of therapy; and whether intention-
to-treat analyses were possible.
Assessment of risk of bias in included studies
In order to assess the risk of bias, two review authors will inde-
pendently assess the quality of the studies included in the review
according to the criteria described by Jüni (Jüni 2001):
Allocation concealment
The authors will assess allocation concealment in each study as
follows:
1. adequate, if the allocation of participants involved a central
independent unit, on-site locked computer, identically appearing
numbered drug bottles or containers prepared by an independent
pharmacist or investigator, or sealed opaque envelopes;
2. unclear, if the method used to conceal the allocation was
not described;
3. inadequate, if the allocation sequence was known to the
investigators who assigned participants or if the study was quasi-
randomised.
Generation of the allocation sequence
The authors will grade each study for allocation concealment as
follows:
1. adequate, if methods of randomisation include using a
random number table, computer-generated lists or similar
methods;
2. unclear, if the study is described as randomised, but no
description of the methods used to allocate participants to
treatment group was described;
3. inadequate, if methods of randomisation include
alternation; the use of case record numbers, dates of birth or day
of the week, and any procedure that is entirely transparent before
allocation.
Blinding (or masking)
The authors will grade each study for blinding as follows:
1. blinding of clinician (person delivering treatment) to
treatment allocation;
2. blinding of participant to treatment allocation;
3. blinding of outcome assessor to treatment allocation.
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Follow-up
The authors will grade each study as to whether numbers of and
reasons for dropouts and withdrawals in all intervention groups
were described; or if it was specified that there were no dropouts
or withdrawals.
They will also report on whether the investigators had performed
a sample-size calculation and if they used an intention-to-treat
(ITT) analysis.
Measures of treatment effect
The authors will include the results from studies that meet the
inclusion criteria and report any of the outcomes of interest in the
subsequent meta-analyses if any data are applicable.
For the dichotomous outcome variables of each individual study,
they will calculate the odds ratio (OR) using a modified ITT
analysis, i.e. if the original investigators did not use ITT analysis,
they will consider dropouts to be failures. They will also calculate
the summary weighted odds ratios and 95% confidence intervals
(CIs) (fixed-effect model) using RevMan (RevMan 2011). The
authors will calculate numbers-needed-to-treat (NNT) and their
95%CIs from the pooledORand its 95%CI for a specific baseline
risk, which is the sum of all the events in the control groups (in
all studies) divided by the total participant numbers in control
groups in all studies using an online calculator (Cates 2003).
For continuous outcomes, they will record the mean relative
change from baseline for each group or mean post-treatment or
post-intervention values and standard deviation. If standard errors
are reported, they will calculate the standard deviations. The au-
thors will then calculate a pooled estimate of treatment effect by
the weighted mean difference and 95% confidence interval (fixed-
effect model) again using RevMan (RevMan 2011).
Unit of analysis issues
For cross-over studies, the authors will calculate the mean treat-
ment differences where possible and enter these using the fixed-ef-
fect generic inverse variance (GIV) analysis in RevMan, to provide
summary weighted differences and 95% CIs (RevMan 2011). In
cross-over studies, if they believe there is a carryover effect which
will outlast any washout period included in the study, they will
include only data from the first arm in themeta-analysis (Elbourne
2002).
If studies report outcomes using different measurement scales, the
authors will estimate the standardised mean difference and 95%
CIs.
Dealing with missing data
The authors will request further information from the primary
investigators where required.
Assessment of heterogeneity
They will describe any heterogeneity between the study results
and test this to see if it reached statistical significance using the
chi-squared test. They will consider heterogeneity to be significant
when the P value is less than 0.10 (Higgins 2011). The authors
also plan to use the I2 statistic where heterogeneity is categorised
such that a value of under 25% is considered low, around 50% is
considered moderate and over 75% is considered a high degree of
heterogeneity (Higgins 2003).
Data synthesis
The authors will include the 95% CI, estimated using a fixed-
effect model. However, they will utilise the random-effects model
whenever there are concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
The authors plan to perform the following a priori subgroup anal-
yses to investigate any heterogeneity which they identify.
1. children (aged 18 years or less) and adults (over 18 years);
2. formulations of the vitamin (single or multivitamin);
3. presence of significant liver synthetic dysfunction (low
baseline albumin);
4. presence of previous bowel resections;
5. presence of pancreatic insufficiency;
6. method of CF diagnosis (i.e. screening versus symptomatic
diagnosis).
Sensitivity analysis
Sensitivity analyses are also planned to assess the impact of the
potentially important factors on the overall outcomes:
1. analysis using a random-effects model;
2. analysis by “treatment received” (as opposed to ITT
analysis).
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
Results of the search
The authors identified a single study in our searches (Wood 2003).
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Excluded studies
The only study identified was excluded because it was not placebo
controlled (see Characteristics of excluded studies).
Risk of bias in included studies
The authors did not find any eligible studies that fulfilled the
inclusion criteria.
Effects of interventions
The authors did not find any eligible studies that fulfilled the
inclusion criteria.
D I S C U S S I O N
Daily vitamin A supplementation is almost universally recom-
mended for people with CF who are pancreatic insufficient. How-
ever, it is unfortunate that there are no controlled studies that have
examined this. The appropriate dose and frequency of vitamin
A supplementation is also unknown. Furthermore while vitamin
A deficiency causes eye and skin disorders, excess vitamin A can
also cause problems (Griffiths 2000; Penniston 2006). Indeed, in-
creasingly data on micronutrients have shown that micronutri-
ent supplementation is only beneficial in states of deficiency and
harmful when no deficiency exists (Chang 2006; Shenkin 2006).
For vitamin A, Griffiths has termed this the ’vitamin A paradox’
as vitamin A supplementation is likely to be “protective against
pneumonia in malnourished children (who are likely to be vita-
min A-deficient) and is paradoxically detrimental for adequately
nourished children” (Griffiths 2000). It is well accepted that peo-
ple with cystic fibrosis and pancreatic insufficiency are at risk of
vitamin A deficiency. However, it is also biologically plausible that
currently, with improved pancreatic replacement therapies and at-
tention to macro nutrition and caloric supplements, the majority
of people with CF are vitamin A sufficient and may not require
daily vitamin A supplementation. Daily supplementation in these
situations at best causes no harm, but it adds a further burden to
the daily medical regimen of people with CF and it is possible that
it may be biologically harmful.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
As therewere no randomised or quasi-randomised controlled trials
identified, we cannot draw any conclusions on the benefits (or
otherwise) of regular administration of vitamin A in people with
cystic fibrosis. Until further data are available, country or region
specific guidelines (e.g. UK CF Trust Nutrition Guidelines (CF
Trust 2002)) on the use and monitoring of vitamin A in people
with cystic fibrosis should be followed.
Implications for research
The need for a well-designed, parallel, adequately-powered, mul-
ticentre, randomised controlled trial to assess if vitamin A supple-
mentation in children and adults with cystic fibrosis is beneficial or
otherwise, is obvious. The study should examine if vitamin A sup-
plementation positively or negatively influences the frequency of
symptoms of vitamin A deficiency or general and respiratory out-
comes. The possible negative effects should be examined in light of
recent data showing possible harm when micronutrients are used
in people who are not micronutrient-deficient. Safety monitoring
during such a study would be important as the current practice is
to use supplementation of vitamin A in people with CF. Vitamin
A levels should be measured before and during the studies when
clinically stable and related to serum albumin and retinol binding
protein. Studies involving both children and adults are required
and results should be related to nutritional status and pancreatic
status. Data relating to appropriate dose and frequency of supple-
mentation are also needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Wood 2003 Non-placebo controlled trial. This trial examined outcomes of forty-six CF patients randomly assigned to either group
A [low dose of supplement (10 mg vitamin E and 500 micro g vitamin A)] or group B [high dose of supplement (200
mg vitamin E, 300 mg vitamin C, 25 mg beta-carotene, 90 micro g Se, and 500 micro g vitamin A)]
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 7 June 2012.
Date Event Description
7 June 2012 New citation required but conclusions have not changed No new studies were included so the conclusions of the
review have not changed
7 June 2012 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register did
not identify any new references potentially eligible for in-
clusion in this review
H I S T O R Y
Protocol first published: Issue 4, 2007
Review first published: Issue 1, 2008
Date Event Description
1 December 2009 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register identified a single
reference which was excluded (Wood 2003).
12 August 2009 Amended Contact details updated.
10 April 2008 Amended Converted to new review format.
10 April 2008 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register did not identify any
trials which might be eligible for inclusion in this review
C O N T R I B U T I O N S O F A U T H O R S
Protocol: CO and AC wrote the protocol. ES reviewed the protocol.
Review: When any studies are identified, CO and AC will select relevant studies, perform data extraction and analysis and write the
review. ES will contribute to writing of the review.
10Vitamin A supplementation for cystic fibrosis (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D E C L A R A T I O N S O F I N T E R E S T
There is no conflict of interest.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
External sources
• National Health and Medical Research Council, Australia.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cystic Fibrosis [∗complications]; Vitamin A [adverse effects; ∗therapeutic use]; Vitamin A Deficiency [prevention & control]; Vitamins
[adverse effects; ∗therapeutic use]
MeSH check words
Humans
11Vitamin A supplementation for cystic fibrosis (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
